Stockscreener 앱 받기
1.745
12.94%
-0.265
전일 마감가:
$2.01
열려 있는:
$1.7
하루 거래량:
6.36M
Relative Volume:
3.36
시가총액:
$212.13M
수익:
$257.24M
순이익/손실:
$-237.89M
주가수익비율:
-0.6712
EPS:
-2.6
순현금흐름:
$-175.17M
1주 성능:
-18.22%
1개월 성능:
+2.94%
6개월 성능:
+75.18%
1년 성능:
+50.86%
1일 변동 폭
$1.64
$1.795
1주일 범위
$1.64
$2.20
52주 변동 폭
$0.71
$2.6158
Coherus Oncology Inc Stock (CHRS) Company Profile
명칭
Coherus Oncology Inc
전화
(650) 649-3530
주소
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.755 | 242.95M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.00 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.16 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
843.34 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.24 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.29 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-23 | 개시 | Oppenheimer | Outperform |
| 2025-09-04 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-08-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-11-17 | 개시 | Robert W. Baird | Outperform |
| 2023-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-07-24 | 개시 | Citigroup | Buy |
| 2023-05-01 | 개시 | Truist | Buy |
| 2023-03-28 | 업그레이드 | UBS | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Neutral |
| 2022-03-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-16 | 개시 | BofA Securities | Neutral |
| 2020-04-17 | 개시 | SunTrust | Buy |
| 2019-08-13 | 개시 | Mizuho | Buy |
| 2019-08-02 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-02 | 재확인 | Maxim Group | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-07 | 개시 | H.C. Wainwright | Buy |
| 2018-08-28 | 개시 | H.C. Wainwright | Buy |
| 2018-03-09 | 재확인 | Maxim Group | Buy |
| 2017-08-08 | 재확인 | JP Morgan | Overweight |
| 2017-06-13 | 재확인 | Maxim Group | Buy |
| 2017-05-05 | 개시 | BMO Capital Markets | Outperform |
| 2016-10-19 | 개시 | Robert W. Baird | Outperform |
| 2016-09-07 | 개시 | Maxim Group | Buy |
| 2016-07-27 | 개시 | Citigroup | Buy |
| 2016-01-20 | 개시 | Credit Suisse | Outperform |
모두보기
Coherus Oncology Inc 주식(CHRS)의 최신 뉴스
Coherus BioSciences stock falls after pricing $50.1 million share offering By Investing.com - Investing.com South Africa
Coherus BioSciences stock falls after pricing $50.1 million share offering - Investing.com
CHRS Successfully Completes Joint Book-Running Offering - GuruFocus
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Coherus Oncology tumbles on $50 mln stock sale - TradingView
Coherus Oncology prices $50.1 million public offering of common stock By Investing.com - Investing.com South Africa
Coherus Prices $50.1 Mln Public Offering; Stock Plunges - Nasdaq
Coherus Oncology (CHRS) Launches $50.1M Public Offering - GuruFocus
Coherus BioSciences Prices $50.1 Million Share Offering - marketscreener.com
Coherus Oncology prices stock offering to raise $50.1M - MSN
Coherus BioSciences (CHRS) Announces Public Stock Offering - GuruFocus
Coherus Oncology Prices Public Offering at $1.75 per Share - Intellectia AI
Cancer-drug firm Coherus to raise $50M for LOQTORZI, clinical development - Stock Titan
Coherus Oncology announces pricing of public offering of common stock - marketscreener.com
Coherus Oncology Announces Pricing Of Public Offering Of Common Stock - TradingView
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock - GlobeNewswire
Coherus Oncology announces proposed public offering of common stock - MSN
Coherus Oncology tumbles on planned equity offering - TradingView
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock - The Manila Times
Coherus plans stock sale to fund LOQTORZI commercialization - Stock Titan
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Coherus Oncology Enters Clinical Supply Agreement with Johnson & Johnson for Combination Cancer Therapy Study - Global Legal Chronicle
Coherus Oncology announces deal with J&J - The Pharma Letter
Johnson & Johnson (JNJ) Partners with Coherus (CHRS) for Cancer Therapy Trial - GuruFocus
Coherus Oncology Inc announces agreement with JanssenSEC filing - marketscreener.com
Coherus Signs Clinical Supply Deal With Janssen Oncology - TipRanks
Coherus Oncology IncAnnounces Agreement With JanssenSEC Filing - TradingView
Coherus Oncology Announces Clinical Supply Agreement with Janssen - TradingView
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Registration-Ready: How 2026’s Clinical Leaders Are Beating Cancer Benchmarks - Cantech Letter
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks - Newswire Canada
Coherus Oncology (CHRS) Taps ATM Facility: Strategic Lifeline or Dilution Trade-Off for Its Pipeline? - simplywall.st
Coherus Oncology (CHRS) Is Up 28.7% After ATM Offering And Bullish CoverageWhat's Changed - Yahoo Finance
Coherus Oncology Surges 30% Following Oppenheimer’s Outperform Rating - timothysykes.com
Coherus Oncology a new outperform at Oppenheimer on tagmokitug potential - MSN
Coherus BioSciences Shares Surge on Analyst Initiation and Capital Move - AD HOC NEWS
Coherus Oncology Stock Surges Following Analyst Ratings and Clinical Developments - timothysykes.com
Improved Revenues Required Before Coherus Oncology, Inc. (NASDAQ:CHRS) Stock's 54% Jump Looks Justified - 富途牛牛
Investors Purchase Large Volume of Coherus Oncology Call Options (NASDAQ:CHRS) - Defense World
Coherus Oncology files prospectus to offer up to $64.9 million in stock - Investing.com Nigeria
Coherus Biosciences Updates ATM Equity Offering Program - TipRanks
Coherus Oncology Files Prospectus Supplement for Stock Offering - TradingView
Oppenheimer Initiates Coherus Oncology (CHRS) at Outperform with $10 Price Target - Intellectia AI
Coherus Oncology (CHRS) Set for Major Upside with Promising Canc - GuruFocus
Coherus Oncology a new outperform at Oppenheimer on tagmokitug potential ( - Seeking Alpha
Coherus Oncology Sees Unusually Large Options Volume (NASDAQ:CHRS) - MarketBeat
Coherus Oncology stock soars 35% after Oppenheimer initiates with massive upside - Investing.com Canada
Oppenheimer Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Oppenheimer Initiates Coverage on Coherus BioSciences With Outperform Rating - marketscreener.com
Oppenheimer Initiates Coverage of Coherus Oncology (CHRS) with Outperform Recommendation - Nasdaq
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading - intellectia.ai
Coherus Oncology Inc (CHRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
1.73%
자본화:
|
볼륨(24시간):